Actinogen Medical Limited (ASX:ACW)
Australia · Delayed Price · Currency is AUD 0.0580
-0.0010 (-1.69%)
Sep 10, 2026, 4:10 PM AEST
Actinogen Medical Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Other Revenue | 12.67 | 5.49 | 9.93 | 4.89 | 3.64 |
| 12.67 | 5.49 | 9.93 | 4.89 | 3.64 | |
Revenue Growth | 130.87% | -44.73% | 103.18% | 34.28% | 83.47% |
Gross Profit | 12.67 | 5.49 | 9.93 | 4.89 | 3.64 |
Selling, General & Admin | 6.94 | 6.46 | 5.93 | 5.05 | 3.27 |
Research & Development | 19.03 | 12.3 | 15.54 | 8.9 | 8.21 |
Amortization of Goodwill & Intangibles | 0.31 | 0.31 | 0.31 | 0.31 | 0.31 |
Operating Expenses | 28.11 | 20.84 | 23.19 | 15.87 | 13.17 |
Operating Income | -15.44 | -15.35 | -13.26 | -10.99 | -9.53 |
Interest Expense | -0.47 | -0.05 | -0.02 | -0.02 | -0.02 |
Interest & Investment Income | 0.5 | 0.69 | 0.29 | 0.37 | 0.04 |
Currency Exchange Gain (Loss) | 0.03 | -0.01 | -0.06 | -0.12 | 0.01 |
EBT Excluding Unusual Items | -15.38 | -14.73 | -13.04 | -10.75 | -9.5 |
Pretax Income | -15.38 | -14.73 | -13.04 | -10.75 | -9.5 |
Net Income | -15.38 | -14.73 | -13.04 | -10.75 | -9.5 |
Net Income to Common | -15.38 | -14.73 | -13.04 | -10.75 | -9.5 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 3,332 | 2,980 | 2,174 | 1,802 | 1,717 |
Shares Outstanding (Diluted) | 3,332 | 2,980 | 2,174 | 1,802 | 1,717 |
Shares Change | 11.82% | 37.04% | 20.69% | 4.92% | 22.20% |
EPS (Basic) | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
EPS (Diluted) | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -17.57 | -7.59 | -16.96 | -8.73 | -9.52 |
Free Cash Flow Per Share | -0.01 | -0.00 | -0.01 | -0.01 | -0.01 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -121.82% | -279.70% | -133.47% | -224.74% | -261.90% |
Profit Margin | -121.35% | -268.37% | -131.34% | -219.98% | -260.91% |
Free Cash Flow Margin | -138.63% | -138.33% | -170.76% | -178.70% | -261.53% |
EBITDA | -15.1 | -15.01 | -12.92 | -10.66 | -9.21 |
EBITDA Margin | -119.15% | -273.48% | -130.10% | -218.10% | -253.12% |
D&A For EBITDA | 0.34 | 0.34 | 0.33 | 0.32 | 0.32 |
EBIT | -15.44 | -15.35 | -13.26 | -10.99 | -9.53 |
EBIT Margin | -121.82% | -279.70% | -133.47% | -224.74% | -261.90% |
Revenue as Reported | 13.17 | 6.17 | 10.22 | 5.25 | 3.68 |